2015
DOI: 10.1136/bjophthalmol-2015-307399
|View full text |Cite
|
Sign up to set email alerts
|

Pathogenesis of thyroid eye disease: review and update on molecular mechanisms

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

3
118
0
20

Year Published

2016
2016
2022
2022

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 173 publications
(155 citation statements)
references
References 114 publications
3
118
0
20
Order By: Relevance
“…Methotrexate improves CAS but may not completely treat DON[80]. Teprotumumab, an anti-IGF-1R monoclonal antibody, is currently under investigation in a clinical trial[81]. …”
Section: Alternative Immunosuppressive Agentsmentioning
confidence: 99%
“…Methotrexate improves CAS but may not completely treat DON[80]. Teprotumumab, an anti-IGF-1R monoclonal antibody, is currently under investigation in a clinical trial[81]. …”
Section: Alternative Immunosuppressive Agentsmentioning
confidence: 99%
“…IL-6 increases immunoglobulin production, β-cells differentiation and enhances thyrotropin receptor (TSHR) expression on the fibroblast surface [21]. Previous studies revealed that thyrotropin receptor is the main autoantigen in TAO in patients with Graves' disease [22]. High level of autoantibodies stimulating TSH receptor (TSAb) correlates with thyroid ophthalmopathy activity and severity in adults and in children [23].…”
Section: Pathogenesis Of Thyroid-associated Ophthalmopathymentioning
confidence: 99%
“…Антитела к рецепторам тиреотропного гормона стимулируют выработку медиаторов, кото-рые регулируют локальный воспалительный ответ, адипогенез и пролиферацию в мягких тканях орбиты при ЭОП [40]. При этом титр данных антител напря-мую коррелирует с активностью ЭОП и снижается после проведения тиреостатического лечения [11].…”
Section: иммунологические исследованияunclassified